Novo Nordisk A/S (NYSE:NVO) Trading Up 3.8% – Still a Buy?

Shares of Novo Nordisk A/S (NYSE:NVO) shot up 3.8% during trading on Wednesday . The stock traded as high as $40.86 and last traded at $40.8020. 19,345,124 shares changed hands during mid-day trading, a decline of 16% from the average session volume of 22,935,594 shares. The stock had previously closed at $39.32.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo announced a strategic partnership with OpenAI to apply generative AI across drug discovery, manufacturing and commercial ops — management says it should speed R&D cycles, improve data-driven decisions and help defend its obesity/diabetes franchise. Article Title
• Positive Sentiment: The U.K. regulator approved a single‑dose 7.2 mg Wegovy pen for adults with obesity, expanding convenience and potentially improving adherence for a core growth product. This supports near‑term commercial momentum for Wegovy. Article Title
• Neutral Sentiment: A mouse study reported GLP‑1 weight‑loss drugs show direct liver benefits independent of weight loss — scientifically positive but preclinical, so limited near‑term commercial impact. Article Title
• Neutral Sentiment: Novo is advancing etavopivat into late‑stage trials for thalassemia, signalling diversification beyond obesity/diabetes; pipeline progress is positive but longer‑dated for valuation impact. Article Title
• Negative Sentiment: Rising competition from Eli Lilly (Foundayo and other agents) is pressuring market share and margins in the obesity market; investors are watching relative efficacy, pricing and prescription trends. Article Title
• Negative Sentiment: Some investors and analysts are trimming exposure — e.g., Vltava Fund sold Novo citing concerns about the financial outlook — and several firms have adjusted price targets after softer-than-expected prescription data for Wegovy. These moves can amplify downside on weak short‑term data. Article Title Article Title

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on NVO. The Goldman Sachs Group reissued a “neutral” rating and issued a $41.00 price objective (down from $63.00) on shares of Novo Nordisk A/S in a report on Monday, March 2nd. Wolfe Research assumed coverage on shares of Novo Nordisk A/S in a research report on Thursday, March 26th. They issued a “peer perform” rating for the company. Jefferies Financial Group upgraded Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a research note on Thursday, February 12th. Sanford C. Bernstein began coverage on Novo Nordisk A/S in a research report on Wednesday, March 18th. They set an “outperform” rating and a $175.00 price target on the stock. Finally, Zacks Research raised Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 10th. Four analysts have rated the stock with a Buy rating and twenty have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $65.56.

Novo Nordisk A/S Trading Up 3.8%

The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.57 and a current ratio of 0.80. The stock has a market capitalization of $182.18 billion, a P/E ratio of 11.76, a price-to-earnings-growth ratio of 8.96 and a beta of 0.73. The firm’s fifty day simple moving average is $40.39 and its 200 day simple moving average is $48.67.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, topping analysts’ consensus estimates of $0.90 by $0.11. The company had revenue of $12.43 billion during the quarter, compared to the consensus estimate of $11.97 billion. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. As a group, equities research analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Announces Dividend

The business also recently announced a dividend, which was paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th were paid a dividend of $1.2751 per share. This represents a dividend yield of 723.0%. The ex-dividend date of this dividend was Monday, March 30th. Novo Nordisk A/S’s payout ratio is presently 50.43%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Rockefeller Capital Management L.P. increased its position in shares of Novo Nordisk A/S by 77.2% during the fourth quarter. Rockefeller Capital Management L.P. now owns 1,340,858 shares of the company’s stock worth $68,223,000 after buying an additional 584,275 shares during the period. Larry Mathis Financial Planning LLC acquired a new position in Novo Nordisk A/S in the fourth quarter valued at $535,000. PeakShares LLC acquired a new position in Novo Nordisk A/S in the fourth quarter valued at $491,000. Union Savings Bank bought a new stake in Novo Nordisk A/S during the fourth quarter valued at $312,000. Finally, Mengis Capital Management Inc. boosted its position in Novo Nordisk A/S by 303.2% during the fourth quarter. Mengis Capital Management Inc. now owns 66,694 shares of the company’s stock valued at $3,393,000 after acquiring an additional 50,154 shares during the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.